Filing Details

Accession Number:
0001209191-14-064841
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-10-24 21:27:23
Reporting Period:
2014-10-22
Filing Date:
2014-10-24
Accepted Time:
2014-10-24 21:27:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1505512 Regulus Therapeutics Inc. RGLS Pharmaceutical Preparations (2834) 264738379
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1178670 Alnylam Pharmaceuticals, Inc. 300 Third Street, 3Rd Floor
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-10-22 109,534 $14.00 5,900,266 No 4 S Direct
Common Stock Disposition 2014-10-23 1,700 $14.24 5,898,566 No 4 S Direct
Common Stock Disposition 2014-10-24 1,850 $15.19 5,896,716 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2014.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.47 to $17.11 inclusive. Full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4 is unavailable.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.30 to $15.45 inclusive. Full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4 is unavailable.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $16.31 inclusive. Full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4 is unavailable.